Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03156621 · ClinicalTrials.gov registry record · Phase 3
Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH)
A Phase 3 study of Homozygous Familial Hypercholesterolemia, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 69
- Enrollment target
- 20
- Study locations
NCT03156621 is a Phase 3 study of Homozygous Familial Hypercholesterolemia that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 69 participants, below the 241-participant average among 6 other Homozygous Familial Hypercholesterolemia trials with a reported enrollment target (71% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT03156621, a Phase 3 study of Homozygous Familial Hypercholesterolemia, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 69 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of the study is to demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) with alirocumab subcutaneous (SC) every 2 weeks (Q2W) in comparison to placebo after 12 weeks of treatment. The secondary objectives of the study are: * To evaluate the effect of alirocumab Q2W on other lipid parameters (ie, apolipoprotein \[Apo\] A-1 and B, non-high-density lipoprotein cholesterol \[non-HDL-C\], total-cholesterol \[TC\], proportion of participants with 15%, 30%, and 50% LDL-C reductions, Lp(a), HDL-C, triglycerides \[TG\]) in participants with HoFH * To evaluate the safety and tolerability of alirocumab SC Q2W in participants with HoFH * To assess the pharmacokinetics of alirocumab SC Q2W in participants with HoFH * To assess the potential development of anti-drug (alirocumab) antibodies
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Alirocumab
Study Locations (20)
Other
- Regeneron Research Site - Prague
- Regeneron Research Site - Marseille
- Regeneron Research Site - Paris
- Regeneron Research Site - Berlin
- Regeneron Research Site - Athens
- Regeneron Research Site - Ioannina
- Regeneron Research Site - Naples
- Regeneron Research Site - Roma
Quebec
- Regeneron Research Site - Chicoutimi
- Regeneron Research Site - Québec
Florida
- Regeneron Research Site - Boca Raton
New York
- Regeneron Research Site - New York
Ohio
- Regeneron Research Site - Cincinnati
Texas
- Regeneron Study Site - Dallas
Tyrol
- Regeneron Research Site - Innsbruck
Hyōgo
- Regeneron Research Site - Nishinomiya
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2017-10-03 |
| Est. Completion | 2020-02-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03156621
The ClinicalTrials.gov registry entry for NCT03156621 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 241-participant average among 6 other Homozygous Familial Hypercholesterolemia trials with a reported enrollment target (71% lower). The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Homozygous Familial Hypercholesterolemia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03156621 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, Quebec, Florida.
Frequently Asked Questions
What is clinical trial NCT03156621 about?
NCT03156621 is a clinical study titled "Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH)". The primary objective of the study is to demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) with alirocumab subcutaneous (SC) every 2 weeks (Q2W) in comparison to placebo after 12 weeks of treatment. The secondary objectives of the study are: * To evaluate the effect of aliro...
What is the current status of trial NCT03156621?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 69 participants. The study started on 2017-10-03. Estimated completion is 2020-02-13.
What conditions does trial NCT03156621 study?
This clinical trial studies the following conditions: Homozygous Familial Hypercholesterolemia.
What interventions are being tested in trial NCT03156621?
The interventions under investigation include: Placebo (DRUG), Alirocumab (DRUG).
Who is sponsoring clinical trial NCT03156621?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03156621 being conducted?
This trial has 20 study locations across Florida, New York, Ohio, Texas, Tyrol. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Homozygous Familial Hypercholesterolemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)
RECRUITING · Phase 3
-
The Rogosin Institute Homozygous Familial Hypercholesterolemia Repository
RECRUITING
-
HoFH, the International Clinical Collaborators Registry
RECRUITING
-
LOWER: Lomitapide Observational Worldwide Evaluation Registry
RECRUITING
-
Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH)
ACTIVE NOT RECRUITING · Phase 2
-
Safety, Tolerability and Efficacy of Microsomal Triglyceride Protein (MTP) Inhibitor
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.